Nicholas C Grassly Selected Research

Vaccines

8/2022	Measuring Vaccine Efficacy Against Infection and Disease in Clinical Trials: Sources and Magnitude of Bias in Coronavirus Disease 2019 (COVID-19) Vaccine Efficacy Estimates.
1/2022	Risk factors for the spread of vaccine-derived type 2 polioviruses after global withdrawal of trivalent oral poliovirus vaccine and the effects of outbreak responses with monovalent vaccine: a retrospective analysis of surveillance data for 51 countries in Africa.
9/2021	Modelling the spread of serotype-2 vaccine derived-poliovirus outbreak in Pakistan and Afghanistan to inform outbreak control strategies in the context of the COVID-19 pandemic.
7/2020	The role of genetic sequencing and analysis in the polio eradication programme.
11/2018	Quantity of Vaccine Poliovirus Shed Determines the Titer of the Serum Neutralizing Antibody Response in Indian Children Who Received Oral Vaccine.
1/2018	Routine immunization in Pakistan: comparison of multiple data sources and identification of factors associated with vaccination.
1/2018	Type 2 Poliovirus Detection after Global Withdrawal of Trivalent Oral Vaccine.
1/2018	Eradicating polio with a vaccine we must stop using.
1/2017	Estimated Effect of Inactivated Poliovirus Vaccine Campaigns, Nigeria and Pakistan, January 2014-April 2016.
1/2017	An assessment of the geographical risks of wild and vaccine-derived poliomyelitis outbreaks in Africa and Asia.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Nicholas C Grassly Research Topics

Disease

22	Poliomyelitis (Polio) 01/2022 - 04/2007
9	Infections 08/2022 - 04/2007
9	acute flaccid myelitis 01/2018 - 10/2008
5	Trachoma 01/2015 - 06/2007
3	Paralysis (Palsy) 01/2022 - 10/2008
3	Blindness (Hysterical Blindness) 01/2015 - 06/2007
2	COVID-19 08/2022 - 09/2021
1	Breakthrough Infections 08/2022
1	Asymptomatic Infections 08/2022
1	Typhoid Fever (Typhoid) 11/2021
1	Fatigue 07/2020
1	Dysbiosis 01/2018
1	Malnutrition (Nutritional Deficiencies) 01/2018
1	Trichiasis 01/2015
1	Cicatrix (Scar) 01/2015
1	Inflammation (Inflammations) 01/2015
1	Diarrhea 09/2014
1	Enterovirus Infections 05/2012
1	Reinfection 01/2009
1	Acquired Immunodeficiency Syndrome (AIDS) 07/2002

Drug/Important Bio-Agent (IBA)

23	VaccinesIBA 08/2022 - 04/2007
10	Oral Poliovirus Vaccine (Sabin Vaccine)IBA 01/2022 - 10/2008
7	Poliovirus VaccinesIBA 01/2016 - 04/2007
6	Anti-Bacterial Agents (Antibiotics)IBA 11/2021 - 06/2007
2	AntibodiesIBA 08/2022 - 01/2018
2	Inactivated Poliovirus Vaccine (Salk Vaccine)FDA Link 01/2015 - 01/2012
1	Ad26COVS1IBA 08/2022
1	dimethylaminonaphthalene- 5- sulfonaminoethylmethylamine (DDNS)IBA 01/2022
1	Blood Group Antigens (Blood Groups)IBA 01/2018
1	Measles VaccineIBA 01/2018
1	Viral ProteinsIBA 01/2018
1	Combined VaccinesIBA 01/2018
1	WastewaterIBA 01/2018
1	insulin receptor-related receptor (IRR)IBA 01/2017
1	EpitopesIBA 01/2008
1	Membrane Proteins (Integral Membrane Proteins)IBA 01/2008
1	dimemorfan (AT 17)IBA 01/2008
1	Immunoglobulin A (IgA)IBA 01/2008

Therapy/Procedure

2	Mass Drug Administration 11/2010 - 01/2009
1	Therapeutics 07/2002